Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein - Test2 - elhamkhani - TriplyDB

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

http://www.wikidata.org/entity/Q29547752

about

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist Enteric microbiome metabolites correlate with response to simvastatin treatment Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis Pitavastatin in cardiometabolic disease: therapeutic profile A comprehensive review on metabolic syndrome Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment Ischemic heart disease in women: a focus on risk factors Statins for primary prevention of venous thromboembolism HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Statins for preventing colorectal adenoma and carcinoma HMG CoA reductase inhibitors (statins) for kidney transplant recipients Statins for the primary prevention of cardiovascular disease Statins for aortic valve stenosis Statins for primary prevention of venous thromboembolism Statins for the primary prevention of cardiovascular disease The cycle of bias in health research: a framework and toolbox for critical appraisal training Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap)Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Are statins diabetogenic?Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional study Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels Stabilization of high-risk plaques Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions Recent advances in pathogenesis, assessment, and treatment of atherosclerosis Statin-induced diabetes: incidence, mechanisms, and implications The role of inflammation in cardiovascular diseases: the predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial disease What happens to cardiovascular system behind the undetectable level of HIV viremia?Management of intracerebral hemorrhage--use of statins CETP Inhibition: Past Failures and Future Hopes 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension

P2860

Q21132391-F2B45C5F-86E5-4014-B6A1-2FF6DEA65C8A Q21135141-AAF37D36-449E-43D3-ADC1-BD72785CE289 Q21144992-3BCC44F9-0B64-4869-A394-1C9F0CEAFA95 Q21246037-ECA64E4F-D577-40CF-99A0-61D8368077C9 Q21284500-570FFAA7-F78F-4E0D-B198-9D6D907C5AD6 Q21561017-1EFB8A90-A25A-47F0-9CA0-397E0F08F37F Q22251459-99638928-CD39-4202-BC6C-BE11AEA0607C Q24187238-46F047A6-A374-4477-9AB5-C91BEDE5D13C Q24194514-493C0FFC-2F5D-4CF8-A31E-A55993BB310D Q24194802-167BD65E-9A49-4D18-A9C9-9A471D908D81 Q24200984-C7C58C2C-2E7E-49CD-925F-E864ED8B6A2A Q24201513-7D89DE34-82F9-4C43-94EC-1FF5CD1ED96E Q24203993-3892D303-F0F9-456E-A673-3ED9AA605FB1 Q24204040-73E764A8-7F60-408F-8318-E3A61D8FB524 Q24234813-7AEA8A66-176A-4C76-B39B-17A84B825DAB Q24289237-5436ACA9-084A-4BE6-8FC2-1C6830DB89DB Q24306597-3AA42FB0-CD84-47BD-A3D8-0D3454845F7C Q24594496-B6BD152F-9265-4BD7-82DE-794E3F522AA5 Q24594814-F480A914-DC16-4455-8734-2980EA719187 Q24602803-E59C53BE-E12C-4FEC-9AC1-491EBFAFC0B0 Q24603957-819EC899-D091-4DEA-A399-8109620CBC1F Q24613405-E30319D6-050F-43F9-A30D-9E820E6495E6 Q24617734-72DFC83E-56B4-4825-B87C-DCA17FEA38D3 Q24626884-C156BEF6-DADF-4418-998F-A24A5C4C735C Q24628361-0EC740C1-8886-4BA3-91CE-5AA1EC018DDB Q24630160-9AF4B3E8-FB30-45CE-8772-9B966EF5C408 Q24630205-DFE3B5CA-AE6B-457D-9121-82AAFD3D6D66 Q24633407-402EBC39-F910-4827-8DD2-B0801040F630 Q24645391-1A03DFF2-676B-40F9-8E97-F69C29F7AE53 Q24649709-09BB82DB-52A9-43ED-BB96-240F13374DF8 Q24658351-5ECD7974-DFC9-4F14-B891-D390941E873C Q26738584-464EC8C2-ABCA-4216-B73A-7691E1335708 Q26740117-F5B8B76C-71F7-4086-AFFC-2FF91CD55EA8 Q26740304-B417DA38-BD32-4C1F-84E3-64818CDB2C86 Q26740677-B7FF6738-9D4F-48B1-8012-BD1A3EB0893A Q26745592-7B5E7198-72E0-47C4-A4B8-603EB524821E Q26749024-1290B6FD-3D51-49DD-A72B-D5BFB1649508 Q26752952-67080D47-B061-4EDB-8A60-FADCBEB08644 Q26753158-3A068008-1E24-4EF8-9937-B19DECE78C21 Q26764784-71E1E610-AD0D-4063-A487-59C5CAC0AE7C

P2860

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

http://www.wikidata.org/entity/Q29547752

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@ast

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@en

type

label

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@ast

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@en

prefLabel

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@ast

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@en

P1433

Q29547752-1A1AED92-DD47-481E-B276-FCC3C5750775

P1476

Q29547752-7FE6A101-8B08-4855-9CEC-1DBEDB9B3822

P2093

Q29547752-0447806D-6A72-4CF8-8BE2-36A71FF03B5A

Q29547752-13B5099C-E5AF-48A8-815F-FC8C913FD52A

Q29547752-14921B54-FCB2-4299-95A1-DF33E1F554D8

Q29547752-1B33F95B-19A6-4D36-8744-E3D2456D478D

Q29547752-294FAF18-9BED-4970-BBAD-7F09834AB9CB

Q29547752-589632AF-44C3-49E3-A63E-56FF5B0F3601

Q29547752-5F480D18-7239-4364-908A-7D3BDF5FA5CF

Q29547752-765B55BF-120A-4F66-B8AA-D1524C9A00F2

Q29547752-8F60D0EF-40EF-4D92-94EE-AD67E05A11A4

Q29547752-B941C4D4-F66D-4037-A3C1-300E8ED3C094

P304

Q29547752-E33E0762-3073-4FFF-BC06-612AEDF6D0A0

P31

Q29547752-9AD6D23F-7B77-4852-9C2B-F3BF83C8B6CB

P3181

Q29547752-49250BDE-40E3-4998-94FE-6AC46CAB4099

P356

Q29547752-58C34761-1518-44A8-8355-6EF6ABA982CB

P407

Q29547752-9DB1854D-F32A-4DC3-AE42-884E6D277516

P433

Q29547752-4544FF27-192C-41DF-9FF9-F480D7576C77

P478

Q29547752-CA0C3A1E-9071-4D82-9C8E-FF8DA1B08133

P577

Q29547752-F63E70E5-7E43-436C-B33F-EEFE770BAF39

P698

Q29547752-6977D1B1-77B0-4CEF-BD74-EFBB3EBB3700

P3181

P356

P1433

The New England Journal of Medicine

P1476

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

@en

P2093

Danielson E

http://www.w3.org/2001/XMLSchema#string

Fonseca FA

http://www.w3.org/2001/XMLSchema#string

Genest J

http://www.w3.org/2001/XMLSchema#string

Glynn RJ

http://www.w3.org/2001/XMLSchema#string

Gotto AM Jr

http://www.w3.org/2001/XMLSchema#string

Kastelein JJ

http://www.w3.org/2001/XMLSchema#string

Koenig W

http://www.w3.org/2001/XMLSchema#string

Libby P

http://www.w3.org/2001/XMLSchema#string

Lorenzatti AJ

http://www.w3.org/2001/XMLSchema#string

MacFadyen JG

http://www.w3.org/2001/XMLSchema#string

P304

2195-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

507187

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0807646

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18997196

http://www.w3.org/2001/XMLSchema#string